Providing affordable essential medicines to African households: The missing policies and institutions for price containment

Social Science and Medicine

Volumn 66, Issue 3, 2008, Pages 569-581

  Tetteh, Ebenezer kwabena ^a,b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Africa; Bilateral dependence solution; Medicine access; Price containment and regulation; Procurement

Indexed keywords

ESTIMATION METHOD; HEALTH CARE; MEDICINE; POLICY MAKING; PRICING POLICY;

ARTICLE; DEVELOPING COUNTRY; DRUG COST; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HOUSEHOLD; HUMAN; INSTITUTIONAL CARE; LOWEST INCOME GROUP;

AFRICA; COST CONTROL; DEVELOPING COUNTRIES; DRUGS, ESSENTIAL; ECONOMICS, PHARMACEUTICAL; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES RESEARCH; INTERNATIONALITY; POVERTY; PRIVATE SECTOR; PUBLIC SECTOR; WORLD HEALTH;

AFRICA;

EID: 37249027321     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2007.10.003     Document Type: Article

References (31)

1. Barnett A., Creese A.L., and Ayivor E. The economics of pharmaceutical policy in Ghana. International Journal of Health Services 10 3 (1982) 479-499
2. Caines, K., & Lush, L. (2004). Impact of public-private partnerships on addressing access to pharmaceuticals in selected low and middle income countries: A synthesis report from studies in Botswana, Sri Lanka, Uganda and Zambia. Global Forum for Health Research.
3. Center for Pharmaceutical Management. Regional pooled procurement of drugs: Evaluation of programs (2002), Management Sciences for Health, Arlington, VA (Submitted to Rockefeller Foundation)
4. Danzon P.M. Pharmaceutical price regulation: National policies versus global interests (1997), AEI Press, Washington, DC
5. Danzon P.M. The economics of parallel trade. Pharmacoeconomics 13 3 (1998) 293-304
6. Danzon P.M. Price comparisons for pharmaceuticals: A review of US and cross-national studies (1999), AEI Press, Washington, DC
7. Danzon P.M., and Towse A. Differential pricing for pharmaceuticals: Reconciling access, R&D and patents. International Journal of Healthcare Finance and Economics 3 (2003) 183-205
8. Ellison, S. F., & Snyder, C. M. (2001). Countervailing power in wholesale pharmaceuticals. Available at: 〈http://papers.ssrn.com/〉.
9. Enemark, U., Alban, A., & Vazquez, E. C. S. (2004). Purchasing pharmaceuticals. World Bank HNP discussion paper. Available at: 〈www.worldbank.org〉.
10. Grabowski H., and Mullins C.D. Pharmacy benefit management, cost effectiveness analysis and drug formulary decisions. Social Science & Medicine 45 4 (1997) 535-544
11. Grace, C. (2003). Equitable pricing of newer essential medicines for developing countries: Evidence for the potential of different mechanisms. Available at: 〈http://www.dfidhealthrc.org/publications/access_medicines.html〉.
12. Huff-Rousselle M., and Burnett F. Cost-containment through pharmaceutical procurement: A Caribbean case study. International Journal of Health Planning and Management 11 2 (1996) 135-137
13. Kearney, A.T. (2004). Healing Mexico's healthcare system. Available at: 〈www.atkearney.com〉.
14. Madrid Y., Velasquez G., and Fefer E. The economics of pharmaceuticals and health sector reform in the Americas. American Journal of Public Health 3 5 (1998) 343-350
15. Maiga F.I., Haddad S., Fournier P., and Gauvin L. Public and private sector responses to essential drugs: A multilevel analysis of drug prescription and selling practices in Mali. Social Science & Medicine 57 5 (2003) 937-948
16. Morgan S., and Hurley J. Internet pharmacy: Prices on the up-and-up. Canadian Medical Association Journal 170 6 (2004) 945-946
17. Quick J.D. Applying management science to developing countries: ABC analysis to plan public drug procurement. Socio-economic Planning and Science 16 1 (1982) 39-50
18. Quick J.D., Boohene N.A., Rankin J., and Mbwasi R.J. Medicines supply in Africa: Should improve through regional collaborations and accredited drug shops. British Medical Journal 331 (2005) 709-710
19. Ridley D.B. Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 23 7 (2005) 651-668
20. Scherer F.M. The pharmaceutical industry-prices and progress. The New England Journal of Medicine 351 9 (2004) 927-932
21. Schweitzer S.O. Pharmaceutical economics and policy (1997), Oxford University Press, New York
22. Sorensen A.T. Insurer-hospital bargaining: Negotiated discounts in post-deregulation Connecticut. Journal of Industrial Economics 51 4 (2003) 469-490
23. UN Millennium Project (2005). Prescription for healthy development: Increasing access to medicines. Report of the Taskforce on HIV/AIDS, Malaria, TB and access to essential medicines, Working Group on Access to Essential Medicines.
24. US General Accounting Office. Pharmacy benefit program: FEHBP plans satisfied with savings and services but retail pharmacies have concerns (1997), GAO/HEHS-97-47, Washington, DC
25. Velasquez G., Correa C., and Weissman R. Cost containment mechanisms for essential medicines including antiretrovirals in China (2003), World Health Organization, Geneva WHO/EDM/PAR/2003.6
26. WHO (2003). Guidelines for price discounts of single-source pharmaceuticals. WHO/EDM/PAR/2003.3.
27. WHO (2004a). The world medicines situation. WHO/EDM/PAR/2004.5.
28. WHO (2004b). Equitable access to essential medicines: A framework of collective action. WHO/EDM/2004.4.
29. Woodfield A. Augmenting referencing of pharmaceuticals in New Zealand with strategic cross-product arrangements. Pharmacoeconomics 19 4 (2001) 337-365
30. World Bank (1994). Importance of pharmaceuticals and essential drug programs in better health for Africa: Experience and lessons learned. Available at: 〈www.worldbank.org〉.
31. World Bank (2004). Tackling human resources and pharmaceutical constraints in millennium development goals: Rising to the challenges. Available at: 〈www.worldbank.org〉.